annex 2 country profiles
|
|
- Sherman Hodges
- 7 years ago
- Views:
Transcription
1 Annex 2 Country profiles
2
3 Afghanistan High TB burden Estimates of TB burden a 213 Rate (per 1 population) 13 (8.4 16) 42 (27 53) Mortality (HIV+TB only).82 (.65.1).27 (.21.33) (includes HIV+TB) 1 (54 17) 34 ( ) (includes HIV+TB) 58 (51 65) 189 ( ) (HIV+TB only).2 (.17.22).64 (.57.72) Case detection, all forms (%) 53 (47 6) Estimates of MDR-TB burden a 213 % of TB cases with MDR-TB 3.7 ( ) 2 (13 27) pulmonary TB cases 82 (56 1 1) 46 (3 61) TB case notifications 213 b Pulmonary, bacteriologically confirmed Pulmonary, clinically diagnosed 8 2 Extrapulmonary 7 56 Total new and relapse 3 57 Previously treated, excluding relapses Total cases notified Among 3 57 new and relapse cases: (11%) cases aged under 15 years; male:female ratio:.7 Reported cases of RR-/MDR-TB 213 Total b Cases tested for RR-/MDR-TB 7 (<1%) 38 (2%) 45 Laboratory-confirmed RR-/MDR-TB cases 73 Patients started on MDR-TB treatment 49 TB/HIV 213 TB patients with known HIV status (26) HIV-positive TB patients 9 (<1) HIV-positive TB patients on co-trimoxazole preventive therapy (CPT) HIV-positive TB patients on antiretroviral therapy (ART) HIV-positive people screened for TB 1 HIV-positive people provided with IPT 12 and relapse cases registered in Previously treated cases, excluding relapse, registered in HIV-positive TB cases, all types, registered in 212 RR-/MDR-TB cases started on second-line treatment in XDR-TB cases started on second-line treatment in 211 Laboratories 213 Smear (per 1 population) 2.2 Culture (per 5 million population).5 Drug susceptibility testing (per 5 million population) Sites performing Xpert MTB/RIF 1 Yes, outside country Financing TB control 214 National TB programme budget (US$ millions) 9.5 % Funded domestically 8% % Funded internationally 57% % Unfunded 35% (rate per 1 population per year) (rate per 1 population) (rate per 1 population per year) Population million Notified (new and relapse) (HIV+TB only) and relapse excluding relapse HIV-positive Data for all years can be downloaded from Global Tuberculosis Report
4 Bangladesh High TB burden High MDR-TB burden Estimates of TB burden a 213 Rate (per 1 population) 8 (51 11) 51 (33 69) Mortality (HIV+TB only).16 (.1.24).1 (.7.15) (includes HIV+TB) 63 (33 1 ) 42 (21 656) (includes HIV+TB) 35 (31 4) 224 ( ) (HIV+TB only).41 (.18.46).26 (.12.3) Case detection, all forms (%) 53 (47 59) Estimates of MDR-TB burden a 213 % of TB cases with MDR-TB 1.4 (.7 2.5) 29 (24 34) pulmonary TB cases 2 1 (1 3 7) 2 6 ( ) TB case notifications 213 b Pulmonary, bacteriologically confirmed Pulmonary, clinically diagnosed Extrapulmonary Total new and relapse Previously treated, excluding relapses Total cases notified Among new cases: 5 51 (3%) cases aged under 15 years; male:female ratio: 1.5 Reported cases of RR-/MDR-TB 213 Total b Cases tested for RR-/MDR-TB 446 (<1%) (5%) Laboratory-confirmed RR-/MDR-TB cases 1 24 Patients started on MDR-TB treatment 684 TB/HIV 213 TB patients with known HIV status 2 67 (1) HIV-positive TB patients 68 (3) HIV-positive TB patients on co-trimoxazole preventive therapy (CPT) 61 (9) HIV-positive TB patients on antiretroviral therapy (ART) 68 (1) HIV-positive people screened for TB 67 HIV-positive people provided with IPT and relapse cases registered in Previously treated cases, excluding relapse, registered in HIV-positive TB cases, all types, registered in RR-/MDR-TB cases started on second-line treatment in XDR-TB cases started on second-line treatment in Laboratories 213 Smear (per 1 population).7 Culture (per 5 million population) <.1 Drug susceptibility testing (per 5 million population) <.1 Sites performing Xpert MTB/RIF 26 Yes, in and outside country (rate per 1 population per year) (rate per 1 population) (rate per 1 population per year) Population million Notified (new and relapse) (HIV+TB only) and relapse excluding relapse HIV-positive Financing TB control 214 National TB programme budget (US$ millions) 57 % Funded domestically 5% % Funded internationally 33% % Unfunded 62% Estimates of TB disease burden have not been approved by the national TB programme in Bangladesh and a joint reassessment will be undertaken following the completion of the prevalence survey planned for 215. b Includes cases with unknown previous TB treatment history Global Tuberculosis Report 214 Data for all years can be downloaded from
5 Brazil High TB burden High HIV burden Estimates of TB burden a 213 Rate (per 1 population) 4.4 ( ) 2.2 ( ) Mortality (HIV+TB only) 2.1 ( ) 1 ( ) (includes HIV+TB) 11 (54 2) 57 (27 99) (includes HIV+TB) 93 (83 11) 46 (41 52) (HIV+TB only) 13 (13 13) 6.5 ( ) Case detection, all forms (%) 82 (72 92) Estimates of MDR-TB burden a 213 % of TB cases with MDR-TB 1.4 (1 1.8) 7.5 ( ) pulmonary TB cases 84 (6 1 1) 94 (71 1 2) TB case notifications 213 b Pulmonary, bacteriologically confirmed Pulmonary, clinically diagnosed Extrapulmonary Total new and relapse 76 2 Previously treated, excluding relapses 7 29 Total cases notified Among 76 2 new and relapse cases: (3%) cases aged under 15 years; male:female ratio: 2. Reported cases of RR-/MDR-TB 213 Total b Cases tested for RR-/MDR-TB 67 (2%) 217 (2%) 895 Laboratory-confirmed RR-/MDR-TB cases 76 Patients started on MDR-TB treatment 717 TB/HIV 213 TB patients with known HIV status (65) HIV-positive TB patients 9 34 (17) HIV-positive TB patients on co-trimoxazole preventive therapy (CPT) HIV-positive TB patients on antiretroviral therapy (ART) HIV-positive people screened for TB HIV-positive people provided with IPT and relapse cases registered in Previously treated cases, excluding relapse, registered in HIV-positive TB cases, all types, registered in RR-/MDR-TB cases started on second-line treatment in XDR-TB cases started on second-line treatment in Laboratories 213 Smear (per 1 population) 1.5 Culture (per 5 million population) 8.6 Drug susceptibility testing (per 5 million population) 1. Sites performing Xpert MTB/RIF Financing TB control 214 National TB programme budget (US$ millions) 79 % Funded domestically 87% % Funded internationally 2% % Unfunded 12% (rate per 1 population per year) (rate per 1 population) (rate per 1 population per year) Population million Notified (new and relapse) (HIV+TB only) and relapse excluding relapse HIV-positive Data for all years can be downloaded from Global Tuberculosis Report
6 Cambodia High TB burden High HIV burden Estimates of TB burden a 213 Rate (per 1 population) 1 (6.3 14) 66 (42 92) Mortality (HIV+TB only).59 (.45.76) 3.9 (3 5) (includes HIV+TB) 11 (91 13) 715 (64 834) (includes HIV+TB) 61 (55 67) 4 ( ) (HIV+TB only) 2.3 ( ) 15 (14 17) Case detection, all forms (%) 62 (56 68) Estimates of MDR-TB burden a 213 % of TB cases with MDR-TB 1.4 (.7 2.5) 11 (4 22) pulmonary TB cases 32 (16 58) 18 (68 37) TB case notifications 213 b Pulmonary, bacteriologically confirmed Pulmonary, clinically diagnosed 9 69 Extrapulmonary Total new and relapse Previously treated, excluding relapses Total cases notified Among new cases: 64 (<1%) cases aged under 15 years; male:female ratio: 1.2 Reported cases of RR-/MDR-TB 213 Total b Cases tested for RR-/MDR-TB 338 (2%) (74%) Laboratory-confirmed RR-/MDR-TB cases 121 Patients started on MDR-TB treatment 121 TB/HIV 213 TB patients with known HIV status (82) HIV-positive TB patients (4) HIV-positive TB patients on co-trimoxazole preventive therapy (CPT) 1 17 (89) HIV-positive TB patients on antiretroviral therapy (ART) 1 1 (89) HIV-positive people screened for TB HIV-positive people provided with IPT and relapse cases registered in Previously treated cases, excluding relapse, registered in HIV-positive TB cases, all types, registered in 212 RR-/MDR-TB cases started on second-line treatment in XDR-TB cases started on second-line treatment in 211 Laboratories 213 Smear (per 1 population) 1.4 Culture (per 5 million population) 1.3 Drug susceptibility testing (per 5 million population).3 Sites performing Xpert MTB/RIF 1 No Financing TB control 214 National TB programme budget (US$ millions) 31 % Funded domestically 4% % Funded internationally 32% % Unfunded 64% (rate per 1 population per year) (rate per 1 population) (rate per 1 population per year) Population million Notified (new and relapse) (HIV+TB only) and relapse excluding relapse HIV-positive Global Tuberculosis Report 214 Data for all years can be downloaded from
7 China High TB burden High HIV burden High MDR-TB burden Estimates of TB burden a 213 Rate (per 1 population) 41 (4 43) 3 ( ) Mortality (HIV+TB only).67 ( ).5 (.2.1) (includes HIV+TB) 1 3 ( ) 94 (82 17) (includes HIV+TB) 98 (91 1 1) 7 (66 77) (HIV+TB only) 4.5 ( ).33 (.31.72) Case detection, all forms (%) 87 (79 93) Estimates of MDR-TB burden a 213 % of TB cases with MDR-TB 5.7 (4.5 7) 26 (22 3) pulmonary TB cases 45 (35 55 ) 9 2 ( ) TB case notifications 213 b Pulmonary, bacteriologically confirmed Pulmonary, clinically diagnosed Extrapulmonary Total new and relapse Previously treated, excluding relapses 8 65 Total cases notified Among new and relapse cases: 4 83 (<1%) cases aged under 15 years; male:female ratio: 2.2 Reported cases of RR-/MDR-TB 213 Total b Cases tested for RR-/MDR-TB (11%) (32%) Laboratory-confirmed RR-/MDR-TB cases Patients started on MDR-TB treatment TB/HIV 213 TB patients with known HIV status (39) HIV-positive TB patients (1) HIV-positive TB patients on co-trimoxazole preventive therapy (CPT) HIV-positive TB patients on antiretroviral therapy (ART) (67) HIV-positive people screened for TB HIV-positive people provided with IPT and relapse cases registered in Previously treated cases, excluding relapse, registered in HIV-positive TB cases, all types, registered in RR-/MDR-TB cases started on second-line treatment in XDR-TB cases started on second-line treatment in Laboratories 213 Smear (per 1 population).2 Culture (per 5 million population) 4.6 Drug susceptibility testing (per 5 million population).9 Sites performing Xpert MTB/RIF 16 Financing TB control 214 National TB programme budget (US$ millions) 347 % Funded domestically 78% % Funded internationally 3% % Unfunded 19% (rate per 1 population per year) (rate per 1 population) (rate per 1 population per year) Population million Notified (new and relapse) (HIV+TB only) and relapse excluding relapse HIV-positive Data for all years can be downloaded from Global Tuberculosis Report
8 Democratic Republic of the Congo High TB burden High HIV burden High MDR-TB burden Estimates of TB burden a 213 Rate (per 1 population) 46 (22 53) 68 (33 78) Mortality (HIV+TB only) 6.4 (.17 24) 9.5 (.25 35) (includes HIV+TB) 37 (19 61) 549 ( ) (includes HIV+TB) 22 (2 24) 326 ( ) (HIV+TB only) 16 (9.8 75) 24 (14 111) Case detection, all forms (%) 51 (47 56) Estimates of MDR-TB burden a 213 % of TB cases with MDR-TB 2.6 (.1 5.5) 13 (.2 28) pulmonary TB cases 2 2 (9 4 7) 9 (14 2 ) TB case notifications 213 b Pulmonary, bacteriologically confirmed Pulmonary, clinically diagnosed Extrapulmonary Total new and relapse Previously treated, excluding relapses Total cases notified Among new cases: 3 86 (4%) cases aged under 15 years; male:female ratio: 1.3 Reported cases of RR-/MDR-TB 213 Total b Cases tested for RR-/MDR-TB 344 (<1%) 1 7 (14%) Laboratory-confirmed RR-/MDR-TB cases 272 Patients started on MDR-TB treatment 147 TB/HIV 213 TB patients with known HIV status (44) HIV-positive TB patients (14) HIV-positive TB patients on co-trimoxazole preventive therapy (CPT) (7) HIV-positive TB patients on antiretroviral therapy (ART) (48) HIV-positive people screened for TB HIV-positive people provided with IPT cases registered in Previously treated cases registered in HIV-positive TB cases, all types, registered in 212 RR-/MDR-TB cases started on second-line treatment in XDR-TB cases started on second-line treatment in 211 Laboratories 213 Smear (per 1 population) 2.3 Culture (per 5 million population).1 Drug susceptibility testing (per 5 million population) <.1 Sites performing Xpert MTB/RIF 26 Financing TB control 214 National TB programme budget (US$ millions) 66 % Funded domestically 3% % Funded internationally 21% % Unfunded 75% (rate per 1 population per year) (rate per 1 population) (rate per 1 population per year) Population million Notified (new and relapse) (HIV+TB only) HIV-positive Global Tuberculosis Report 214 Data for all years can be downloaded from
9 Ethiopia High TB burden High HIV burden High MDR-TB burden Estimates of TB burden a 213 Rate (per 1 population) 3 (16 47) 32 (17 5) Mortality (HIV+TB only) 5.6 (3.6 8) 5.9 ( ) (includes HIV+TB) 2 (16 24) 211 (17 257) (includes HIV+TB) 21 (18 26) 224 ( ) (HIV+TB only) 22 (19 32) 24 (21 33) Case detection, all forms (%) 62 (51 74) Estimates of MDR-TB burden a 213 % of TB cases with MDR-TB 1.6 (.9 2.8) 12 (5.6 21) pulmonary TB cases 1 4 (8 2 5) TB case notifications 213 b Pulmonary, bacteriologically confirmed Pulmonary, clinically diagnosed Extrapulmonary Total new and relapse Previously treated, excluding relapses Total cases notified Among new cases: (16%) cases aged under 15 years; male:female ratio: 1.2 Reported cases of RR-/MDR-TB 213 Total b Cases tested for RR-/MDR-TB 212 (<1%) Laboratory-confirmed RR-/MDR-TB cases 558 Patients started on MDR-TB treatment 413 TB/HIV 213 TB patients with known HIV status (71) HIV-positive TB patients (11) HIV-positive TB patients on co-trimoxazole preventive therapy (CPT) HIV-positive TB patients on antiretroviral therapy (ART) 7 55 (68) HIV-positive people screened for TB HIV-positive people provided with IPT cases registered in Previously treated cases registered in HIV-positive TB cases, all types, registered in 212 RR-/MDR-TB cases started on second-line treatment in XDR-TB cases started on second-line treatment in 211 Laboratories 213 Smear (per 1 population) 2.2 Culture (per 5 million population).4 Drug susceptibility testing (per 5 million population).4 Sites performing Xpert MTB/RIF 23 (rate per 1 population per year) (rate per 1 population) (rate per 1 population per year) Population million Notified (new and relapse) (HIV+TB only) HIV-positive Financing TB control 214 National TB programme budget (US$ millions) 94 % Funded domestically 7% % Funded internationally 3% % Unfunded 63% Estimates of TB disease burden for Ethiopia are provisional pending a joint review by WHO and the MOH in early Data for all years can be downloaded from Global Tuberculosis Report
10 India High TB burden High HIV burden High MDR-TB burden Estimates of TB burden a 213 Rate (per 1 population) 24 (15 35) 19 (12 28) Mortality (HIV+TB only) 38 (31 44) 3 ( ) (includes HIV+TB) 2 6 ( ) 211 ( ) (includes HIV+TB) 2 1 (2 2 3) 171 ( ) (HIV+TB only) 12 (1 14) 9.7 (8.3 11) Case detection, all forms (%) 58 (54 61) Estimates of MDR-TB burden a 213 % of TB cases with MDR-TB 2.2 ( ) 15 (11 19) pulmonary TB cases 2 (17 24 ) 41 (3 52 ) TB case notifications 213 b Pulmonary, bacteriologically confirmed Pulmonary, clinically diagnosed Extrapulmonary Total new and relapse Previously treated, excluding relapses Total cases notified Among new and relapse cases: (5%) cases aged under 15 years Reported cases of RR-/MDR-TB 213 Total b Cases tested for RR-/MDR-TB Laboratory-confirmed RR-/MDR-TB cases Patients started on MDR-TB treatment TB/HIV 213 TB patients with known HIV status (63) HIV-positive TB patients (5) HIV-positive TB patients on co-trimoxazole preventive therapy (CPT) (95) HIV-positive TB patients on antiretroviral therapy (ART) (88) HIV-positive people screened for TB HIV-positive people provided with IPT and relapse cases registered in Previously treated cases, excluding relapse, registered in HIV-positive TB cases, all types, registered in RR-/MDR-TB cases started on second-line treatment in XDR-TB cases started on second-line treatment in 211 Laboratories 213 Smear (per 1 population) 1. Culture (per 5 million population).2 Drug susceptibility testing (per 5 million population).2 Sites performing Xpert MTB/RIF 54 (rate per 1 population per year) (rate per 1 population) (rate per 1 population per year) Population million Notified (new and relapse) (HIV+TB only) and relapse excluding relapse HIV-positive Financing TB control 214 National TB programme budget (US$ millions) 252 % Funded domestically 66% % Funded internationally 34% % Unfunded % Estimates for India have not yet been officially approved by the Ministry of Health & Family Welfare, Government of India, and should therefore be considered provisional Global Tuberculosis Report 214 Data for all years can be downloaded from
11 Indonesia High TB burden High HIV burden High MDR-TB burden Estimates of TB burden a 213 Rate (per 1 population) 64 (36 93) 25 (14 37) Mortality (HIV+TB only) 3.9 ( ) 1.6 ( ) (includes HIV+TB) 68 (34 1 1) 272 (138 45) (includes HIV+TB) 46 (41 52) 183 (164 27) (HIV+TB only) 15 (8.7 2) 5.8 ( ) Case detection, all forms (%) 71 (63 8) Estimates of MDR-TB burden a 213 % of TB cases with MDR-TB 1.9 ( ) 12 (8.1 17) pulmonary TB cases 5 7 ( ) 1 1 (77 1 6) TB case notifications 213 b Pulmonary, bacteriologically confirmed Pulmonary, clinically diagnosed Extrapulmonary Total new and relapse Previously treated, excluding relapses Total cases notified Among new and relapse cases: (8%) cases aged under 15 years; male:female ratio: 1.4 Reported cases of RR-/MDR-TB 213 Total b Cases tested for RR-/MDR-TB 53 (<1%) 3 74 (39%) Laboratory-confirmed RR-/MDR-TB cases 912 Patients started on MDR-TB treatment 89 TB/HIV 213 TB patients with known HIV status (2) HIV-positive TB patients (21) HIV-positive TB patients on co-trimoxazole preventive therapy (CPT) 477 (3) HIV-positive TB patients on antiretroviral therapy (ART) 332 (21) HIV-positive people screened for TB HIV-positive people provided with IPT and relapse cases registered in Previously treated cases, excluding relapse, registered in HIV-positive TB cases, all types, registered in RR-/MDR-TB cases started on second-line treatment in XDR-TB cases started on second-line treatment in Laboratories 213 Smear (per 1 population) 2.2 Culture (per 5 million population).4 Drug susceptibility testing (per 5 million population).2 Sites performing Xpert MTB/RIF 23 Financing TB control 214 National TB programme budget (US$ millions) 127 % Funded domestically 13% % Funded internationally 3% % Unfunded 57% (rate per 1 population per year) (rate per 1 population) (rate per 1 population per year) Population million Notified (new and relapse) (HIV+TB only) and relapse excluding relapse HIV-positive Data for all years can be downloaded from Global Tuberculosis Report
12 Kenya High TB burden High HIV burden Estimates of TB burden a 213 Rate (per 1 population) 9.1 (5.5 12) 2 (12 27) Mortality (HIV+TB only) 9.5 (7.5 12) 21 (17 27) (includes HIV+TB) 13 (69 2) 283 ( ) (includes HIV+TB) 12 (12 12) 268 ( ) (HIV+TB only) 48 (47 5) 19 (15 112) Case detection, all forms (%) 75 (74 77) Estimates of MDR-TB burden a 213 % of TB cases with MDR-TB 2.6 (.1 5.5) 13 (.2 28) pulmonary TB cases 1 7 (7 3 7) 1 1 (17 2 3) TB case notifications 213 b Pulmonary, bacteriologically confirmed Pulmonary, clinically diagnosed Extrapulmonary Total new and relapse Previously treated, excluding relapses Total cases notified Among new cases: (6%) cases aged under 15 years; male:female ratio: 1.4 Reported cases of RR-/MDR-TB 213 Total b Cases tested for RR-/MDR-TB 127 (<1%) (22%) Laboratory-confirmed RR-/MDR-TB cases 16 Patients started on MDR-TB treatment 29 TB/HIV 213 TB patients with known HIV status (94) HIV-positive TB patients (38) HIV-positive TB patients on co-trimoxazole preventive therapy (CPT) (99) HIV-positive TB patients on antiretroviral therapy (ART) (84) HIV-positive people screened for TB HIV-positive people provided with IPT and relapse cases registered in Previously treated cases, excluding relapse, registered in HIV-positive TB cases, all types, registered in RR-/MDR-TB cases started on second-line treatment in XDR-TB cases started on second-line treatment in 211 Laboratories 213 Smear (per 1 population) 4.2 Culture (per 5 million population).8 Drug susceptibility testing (per 5 million population).7 Sites performing Xpert MTB/RIF 21 No Financing TB control 214 National TB programme budget (US$ millions) 57 % Funded domestically 23% % Funded internationally 17% % Unfunded 6% (rate per 1 population per year) (rate per 1 population) (rate per 1 population per year) Population million Notified (new and relapse) (HIV+TB only) and relapse excluding relapse HIV-positive Global Tuberculosis Report 214 Data for all years can be downloaded from
13 Mozambique High TB burden High HIV burden Estimates of TB burden a 213 Rate (per 1 population) 18 (9.4 26) 69 (36 11) Mortality (HIV+TB only) 38 (27 51) 148 (15 198) (includes HIV+TB) 14 (78 23) 559 (33 893) (includes HIV+TB) 14 (11 18) 552 (442 68) (HIV+TB only) 81 (64 1) 312 ( ) Case detection, all forms (%) 37 (3 47) Estimates of MDR-TB burden a 213 % of TB cases with MDR-TB 3.5 ( ) 11 ( 25) pulmonary TB cases 1 5 (95 2 1) 83 ( 1 9) TB case notifications 213 b Pulmonary, bacteriologically confirmed Pulmonary, clinically diagnosed Extrapulmonary Total new and relapse Previously treated, excluding relapses Total cases notified Reported cases of RR-/MDR-TB 213 Total b Cases tested for RR-/MDR-TB 634 (3%) 653 (9%) Laboratory-confirmed RR-/MDR-TB cases 444 Patients started on MDR-TB treatment 313 TB/HIV 213 TB patients with known HIV status (91) HIV-positive TB patients (56) HIV-positive TB patients on co-trimoxazole preventive therapy (CPT) (97) HIV-positive TB patients on antiretroviral therapy (ART) (72) HIV-positive people screened for TB HIV-positive people provided with IPT cases registered in Previously treated cases registered in 212 HIV-positive TB cases, all types, registered in 212 RR-/MDR-TB cases started on second-line treatment in XDR-TB cases started on second-line treatment in 211 Laboratories 213 Smear (per 1 population) 1.3 Culture (per 5 million population).6 Drug susceptibility testing (per 5 million population).4 Sites performing Xpert MTB/RIF 14 Yes, outside country Financing TB control 214 National TB programme budget (US$ millions) 19 % Funded domestically % Funded internationally 22% % Unfunded 78% (rate per 1 population per year) (rate per 1 population) (rate per 1 population per year) Population million Notified (new and relapse) (HIV+TB only) HIV-positive Data for all years can be downloaded from Global Tuberculosis Report
14 Myanmar High TB burden High HIV burden High MDR-TB burden Estimates of TB burden a 213 Rate (per 1 population) 26 (16 38) 49 (29 71) Mortality (HIV+TB only) 4.3 ( ) 8 ( ) (includes HIV+TB) 25 (19 32) 473 ( ) (includes HIV+TB) 2 (18 22) 373 (34 413) (HIV+TB only) 17 (16 18) 33 (3 34) Case detection, all forms (%) 68 (61 74) Estimates of MDR-TB burden a 213 % of TB cases with MDR-TB 5 ( ) 27 (15 39) pulmonary TB cases 5 7 ( ) 3 3 ( ) TB case notifications 213 b c (rate per 1 population per year) (rate per 1 population) Population million Pulmonary, bacteriologically confirmed Pulmonary, clinically diagnosed Extrapulmonary Total new and relapse Previously treated, excluding relapses 7 37 Total cases notified Reported cases of RR-/MDR-TB 213 Total c Cases tested for RR-/MDR-TB (13%) (7%) Laboratory-confirmed RR-/MDR-TB cases Patients started on MDR-TB treatment 667 TB/HIV 213 TB patients with known HIV status (12) HIV-positive TB patients (32) HIV-positive TB patients on co-trimoxazole preventive therapy (CPT) (89) HIV-positive TB patients on antiretroviral therapy (ART) (74) HIV-positive people screened for TB HIV-positive people provided with IPT 468 cases registered in Previously treated cases registered in HIV-positive TB cases, all types, registered in 212 RR-/MDR-TB cases started on second-line treatment in XDR-TB cases started on second-line treatment in 211 Laboratories 213 Smear (per 1 population).9 Culture (per 5 million population).3 Drug susceptibility testing (per 5 million population).2 Sites performing Xpert MTB/RIF 24 Yes, outside country Financing TB control 214 National TB programme budget (US$ millions) 36 % Funded domestically 15% % Funded internationally 49% % Unfunded 35% b Case notifications were updated after TB burden estimates had already been produced. c Includes cases with unknown previous TB treatment history. (rate per 1 population per year) Notified (new and relapse) (HIV+TB only) HIV-positive Global Tuberculosis Report 214 Data for all years can be downloaded from
15 Nigeria High TB burden High HIV burden High MDR-TB burden Estimates of TB burden a 213 Rate (per 1 population) 16 (68 27) 94 (39 156) Mortality (HIV+TB only) 85 (47 14) 49 (27 78) (includes HIV+TB) 57 (43 73) 326 ( ) (includes HIV+TB) 59 (34 88) 338 (194 56) (HIV+TB only) 14 (81 22) 81 (47 124) Case detection, all forms (%) 16 (11 28) Estimates of MDR-TB burden a 213 % of TB cases with MDR-TB 2.9 (2.1 4) 14 (1 19) pulmonary TB cases 2 5 ( ) 1 2 (86 1 6) TB case notifications 213 b Pulmonary, bacteriologically confirmed Pulmonary, clinically diagnosed Extrapulmonary Total new and relapse Previously treated, excluding relapses Total cases notified 1 41 Among 1 41 new and relapse cases: (6%) cases aged under 15 years; male:female ratio: 1.5 Reported cases of RR-/MDR-TB 213 Total b Cases tested for RR-/MDR-TB 1 41 Laboratory-confirmed RR-/MDR-TB cases 669 Patients started on MDR-TB treatment 426 TB/HIV 213 TB patients with known HIV status (88) HIV-positive TB patients (22) HIV-positive TB patients on co-trimoxazole preventive therapy (CPT) (87) HIV-positive TB patients on antiretroviral therapy (ART) (67) HIV-positive people screened for TB HIV-positive people provided with IPT cases registered in Previously treated cases registered in HIV-positive TB cases, all types, registered in RR-/MDR-TB cases started on second-line treatment in XDR-TB cases started on second-line treatment in 211 Laboratories 213 Smear (per 1 population).9 Culture (per 5 million population).1 Drug susceptibility testing (per 5 million population) <.1 Sites performing Xpert MTB/RIF 49 Yes, outside country Financing TB control 214 National TB programme budget (US$ millions) 139 % Funded domestically 9% % Funded internationally 38% % Unfunded 53% (rate per 1 population per year) (rate per 1 population) (rate per 1 population per year) Population million Notified (new and relapse) (HIV+TB only) HIV-positive Data for all years can be downloaded from Global Tuberculosis Report
16 Pakistan High TB burden High MDR-TB burden Estimates of TB burden a 213 Rate (per 1 population) 1 (45 17) 56 (25 92) Mortality (HIV+TB only).97 ( ).53 (.28.86) (includes HIV+TB) 62 (52 74) 342 (284 46) (includes HIV+TB) 5 (37 65) 275 (25 357) (HIV+TB only) 2.6 ( ) 1.4 ( ) Case detection, all forms (%) 58 (44 78) Estimates of MDR-TB burden a 213 % of TB cases with MDR-TB 4.3 ( ) 19 (14 25) pulmonary TB cases 9 9 ( ) 3 1 (2 2 4 ) TB case notifications 213 b Pulmonary, bacteriologically confirmed Pulmonary, clinically diagnosed Extrapulmonary Total new and relapse Previously treated, excluding relapses Total cases notified Among new cases: (1%) cases aged under 15 years; male:female ratio: 1. Reported cases of RR-/MDR-TB 213 Total b Cases tested for RR-/MDR-TB (5%) 3 51 (22%) Laboratory-confirmed RR-/MDR-TB cases Patients started on MDR-TB treatment TB/HIV 213 TB patients with known HIV status 8 36 (3) HIV-positive TB patients 36 (<1) HIV-positive TB patients on co-trimoxazole preventive therapy (CPT) HIV-positive TB patients on antiretroviral therapy (ART) HIV-positive people screened for TB HIV-positive people provided with IPT cases registered in Previously treated cases registered in HIV-positive TB cases, all types, registered in 212 RR-/MDR-TB cases started on second-line treatment in XDR-TB cases started on second-line treatment in Laboratories 213 Smear (per 1 population).8 Culture (per 5 million population).3 Drug susceptibility testing (per 5 million population).2 Sites performing Xpert MTB/RIF 32 (rate per 1 population per year) (rate per 1 population) (rate per 1 population per year) 1 5 Population million Notified (new and relapse) (HIV+TB only) HIV-positive Financing TB control 214 National TB programme budget (US$ millions) 114 % Funded domestically % Funded internationally 3% % Unfunded 7% Global Tuberculosis Report 214 Data for all years can be downloaded from
17 Philippines High TB burden High MDR-TB burden Estimates of TB burden a 213 Rate (per 1 population) 27 (25 29) 27 (25 29) Mortality (HIV+TB only).58 (.42.77).6 (.4.8) (includes HIV+TB) 43 (38 49) 438 ( ) (includes HIV+TB) 29 (26 33) 292 ( ) (HIV+TB only).31 (.18.34).32 (.18.35) Case detection, all forms (%) 8 (71 9) Estimates of MDR-TB burden a 213 % of TB cases with MDR-TB 2 ( ) 21 (16 29) pulmonary TB cases 4 4 (3 1 6 ) 4 1 (3 5 5) TB case notifications 213 b Pulmonary, bacteriologically confirmed Pulmonary, clinically diagnosed Extrapulmonary Total new and relapse Previously treated, excluding relapses Total cases notified Among new cases: 2 65 (2%) cases aged under 15 years; male:female ratio: 2.3 Reported cases of RR-/MDR-TB 213 Total b Cases tested for RR-/MDR-TB (3%) (7%) Laboratory-confirmed RR-/MDR-TB cases Patients started on MDR-TB treatment TB/HIV 213 TB patients with known HIV status 5 34 (2) HIV-positive TB patients 26 (<1) HIV-positive TB patients on co-trimoxazole preventive therapy (CPT) HIV-positive TB patients on antiretroviral therapy (ART) HIV-positive people screened for TB 3 6 HIV-positive people provided with IPT cases registered in Previously treated cases registered in 212 HIV-positive TB cases, all types, registered in 212 RR-/MDR-TB cases started on second-line treatment in XDR-TB cases started on second-line treatment in Laboratories 213 Smear (per 1 population) 2.6 Culture (per 5 million population).9 Drug susceptibility testing (per 5 million population).2 Sites performing Xpert MTB/RIF 16 Financing TB control 214 National TB programme budget (US$ millions) 117 % Funded domestically 27% % Funded internationally 25% % Unfunded 48% (rate per 1 population per year) (rate per 1 population) (rate per 1 population per year) J Population million Notified (new and relapse) (HIV+TB only) HIV-positive Data for all years can be downloaded from Global Tuberculosis Report
18 Russian Federation High TB burden High HIV burden High MDR-TB burden Estimates of TB burden a 213 Rate (per 1 population) 17 (17 18) 12 (12 13) Mortality (HIV+TB only) 1.4 (1 1.9).98 (.7 1.3) (includes HIV+TB) 16 (74 29) 114 (51 21) (includes HIV+TB) 13 (12 14) 89 (82 1) (HIV+TB only) 7.9 ( ) 5.5 ( ) Case detection, all forms (%) 83 (74 91) Estimates of MDR-TB burden a 213 % of TB cases with MDR-TB 19 (14 25) 49 (4 59) pulmonary TB cases 16 (11 2 ) 25 (2 3 ) TB case notifications 213 b Pulmonary, bacteriologically confirmed Pulmonary, clinically diagnosed Extrapulmonary Total new and relapse Previously treated, excluding relapses Total cases notified Among new cases: (4%) cases aged under 15 years; male:female ratio: 2.2 Reported cases of RR-/MDR-TB 213 Total b Cases tested for RR-/MDR-TB (84%) (23%) Laboratory-confirmed RR-/MDR-TB cases Patients started on MDR-TB treatment TB/HIV 213 TB patients with known HIV status c HIV-positive TB patients 4 99 HIV-positive TB patients on co-trimoxazole preventive therapy (CPT) HIV-positive TB patients on antiretroviral therapy (ART) HIV-positive people screened for TB HIV-positive people provided with IPT and relapse cases registered in Previously treated cases, excluding relapse, registered in HIV-positive TB cases, all types, registered in 212 RR-/MDR-TB cases started on second-line treatment in XDR-TB cases started on second-line treatment in 211 Laboratories 213 Smear (per 1 population) 3.7 Culture (per 5 million population) 11.6 Drug susceptibility testing (per 5 million population) 7.6 Sites performing Xpert MTB/RIF 72 (rate per 1 population per year) (rate per 1 population) (rate per 1 population per year) Population million Notified (new and relapse) (HIV+TB only) and relapse excluding relapse HIV-positive Financing TB control 214 National TB programme budget (US$ millions) % Funded domestically 1% % Funded internationally % Unfunded % c The reported number of TB patients with known HIV status is for new TB patients in the civilian sector only. It was not possible to calculate the percentage of all TB patients with known HIV status Global Tuberculosis Report 214 Data for all years can be downloaded from
19 South Africa High TB burden High HIV burden High MDR-TB burden Estimates of TB burden a 213 Rate (per 1 population) 25 (15 38) 48 (28 73) Mortality (HIV+TB only) 64 (47 83) 121 (9 158) (includes HIV+TB) 38 (21 59) 715 ( ) (includes HIV+TB) 45 (41 52) 86 (776 98) (HIV+TB only) 27 (24 31) 52 ( ) Case detection, all forms (%) 69 (6 76) Estimates of MDR-TB burden a 213 % of TB cases with MDR-TB 1.8 ( ) 6.7 ( ) pulmonary TB cases 4 6 ( ) 2 2 ( ) TB case notifications 213 b Pulmonary, bacteriologically confirmed Pulmonary, clinically diagnosed Extrapulmonary Total new and relapse Previously treated, excluding relapses Total cases notified Among new and relapse cases: (12%) cases aged under 15 years; male:female ratio: 1.2 Reported cases of RR-/MDR-TB 213 Total b Cases tested for RR-/MDR-TB Laboratory-confirmed RR-/MDR-TB cases Patients started on MDR-TB treatment TB/HIV 213 TB patients with known HIV status (9) HIV-positive TB patients (62) HIV-positive TB patients on co-trimoxazole preventive therapy (CPT) (81) HIV-positive TB patients on antiretroviral therapy (ART) (66) HIV-positive people screened for TB HIV-positive people provided with IPT and relapse cases registered in Previously treated cases, excluding relapse, registered in HIV-positive TB cases, all types, registered in RR-/MDR-TB cases started on second-line treatment in XDR-TB cases started on second-line treatment in Laboratories 213 Smear (per 1 population).4 Culture (per 5 million population) 1.4 Drug susceptibility testing (per 5 million population) 1.4 Sites performing Xpert MTB/RIF 27 Financing TB control 214 National TB programme budget (US$ millions) 162 % Funded domestically 84% % Funded internationally 16% % Unfunded % (rate per 1 population per year) (rate per 1 population) (rate per 1 population per year) Population million Notified (new and relapse) (HIV+TB only) and relapse excluding relapse HIV-positive Data for all years can be downloaded from Global Tuberculosis Report
20 Thailand High TB burden High HIV burden Estimates of TB burden a 213 Rate (per 1 population) 8.1 (4.9 12) 12 (7.3 18) Mortality (HIV+TB only) 1.9 ( ) 2.8 (2 3.6) (includes HIV+TB) 1 (48 17) 149 (72 252) (includes HIV+TB) 8 (71 9) 119 (16 134) (HIV+TB only) 12 (1 13) 17 (15 19) Case detection, all forms (%) 8 (71 89) Estimates of MDR-TB burden a 213 % of TB cases with MDR-TB 2 ( ) 19 (14 25) pulmonary TB cases 1 (73 1 5) 88 (64 1 2) TB case notifications 213 b Pulmonary, bacteriologically confirmed Pulmonary, clinically diagnosed Extrapulmonary Total new and relapse Previously treated, excluding relapses Total cases notified Reported cases of RR-/MDR-TB 213 Total b Cases tested for RR-/MDR-TB (1%) 54 (12%) Laboratory-confirmed RR-/MDR-TB cases 23 Patients started on MDR-TB treatment 23 TB/HIV 213 TB patients with known HIV status (83) HIV-positive TB patients (15) HIV-positive TB patients on co-trimoxazole preventive therapy (CPT) 5 26 (63) HIV-positive TB patients on antiretroviral therapy (ART) 4 89 (59) HIV-positive people screened for TB HIV-positive people provided with IPT and relapse cases registered in Previously treated cases, excluding relapse, registered in HIV-positive TB cases, all types, registered in RR-/MDR-TB cases started on second-line treatment in 211 XDR-TB cases started on second-line treatment in 211 Laboratories 213 Smear (per 1 population) 1.6 Culture (per 5 million population) 4.8 Drug susceptibility testing (per 5 million population) 1.3 Sites performing Xpert MTB/RIF 14 (rate per 1 population per year) (rate per 1 population) (rate per 1 population per year) Population million Notified (new and relapse) (HIV+TB only) Financing TB control 214 National TB programme budget (US$ millions) 16 c % Funded domestically 54% % Funded internationally 33% % Unfunded 13% c Data reported are only national level budgets for the Bureau of TB and the National Health Security Office, and do not include provincial, local and private sector budgets and relapse excluding relapse HIV-positive Global Tuberculosis Report 214 Data for all years can be downloaded from
21 Uganda High TB burden High HIV burden Estimates of TB burden a 213 Rate (per 1 population) 4.1 ( ) 11 (5.8 18) Mortality (HIV+TB only) 7.2 (5 9.9) 19 (13 26) (includes HIV+TB) 58 (32 91) 154 (85 243) (includes HIV+TB) 62 (56 73) 166 ( ) (HIV+TB only) 32 (29 38) 86 (77 12) Case detection, all forms (%) 73 (63 81) Estimates of MDR-TB burden a 213 % of TB cases with MDR-TB 1.4 (.6 2.2) 12 (6.8 19) pulmonary TB cases 54 (23 84) 49 (27 78) TB case notifications 213 b Pulmonary, bacteriologically confirmed Pulmonary, clinically diagnosed Extrapulmonary Total new and relapse Previously treated, excluding relapses 2 11 Total cases notified Among new cases: 649 (3%) cases aged under 15 years; male:female ratio: 1.9 Reported cases of RR-/MDR-TB 213 Total b Cases tested for RR-/MDR-TB 92 (<1%) 397 (1%) 549 Laboratory-confirmed RR-/MDR-TB cases 117 Patients started on MDR-TB treatment 199 TB/HIV 213 TB patients with known HIV status (91) HIV-positive TB patients (48) HIV-positive TB patients on co-trimoxazole preventive therapy (CPT) (96) HIV-positive TB patients on antiretroviral therapy (ART) (65) HIV-positive people screened for TB HIV-positive people provided with IPT and relapse cases registered in Previously treated cases, excluding relapse, registered in HIV-positive TB cases, all types, registered in 212 RR-/MDR-TB cases started on second-line treatment in XDR-TB cases started on second-line treatment in 211 Laboratories 213 Smear (per 1 population) 3.5 Culture (per 5 million population).5 Drug susceptibility testing (per 5 million population).5 Sites performing Xpert MTB/RIF 37 Financing TB control 214 National TB programme budget (US$ millions) 39 % Funded domestically 5% % Funded internationally 14% % Unfunded 81% (rate per 1 population per year) (rate per 1 population) (rate per 1 population per year) Population million Notified (new and relapse) (HIV+TB only) and relapse excluding relapse HIV-positive Data for all years can be downloaded from Global Tuberculosis Report
22 United Republic of Tanzania High TB burden High HIV burden High MDR-TB BUrden Estimates of TB burden a 213 Rate (per 1 population) 6 ( ) 12 (7 17) Mortality (HIV+TB only) 6.1 ( ) 12 (9.8 15) (includes HIV+TB) 85 (45 14) 172 (92 277) (includes HIV+TB) 81 (77 84) 164 (157 17) (HIV+TB only) 3 (29 31) 61 (58 63) Case detection, all forms (%) 79 (77 83) Estimates of MDR-TB burden a 213 % of TB cases with MDR-TB 1.1 (.5 2) 3.1 (.9 7.9) pulmonary TB cases 53 (24 96) 86 (25 22) TB case notifications 213 b Pulmonary, bacteriologically confirmed Pulmonary, clinically diagnosed Extrapulmonary Total new and relapse Previously treated, excluding relapses Total cases notified Among new cases: (11%) cases aged under 15 years; male:female ratio: 1.4 Reported cases of RR-/MDR-TB 213 Total b Cases tested for RR-/MDR-TB (5%) 728 (26%) 2 2 Laboratory-confirmed RR-/MDR-TB cases 64 Patients started on MDR-TB treatment 28 TB/HIV 213 TB patients with known HIV status (83) HIV-positive TB patients 2 32 (37) HIV-positive TB patients on co-trimoxazole preventive therapy (CPT) (98) HIV-positive TB patients on antiretroviral therapy (ART) (73) HIV-positive people screened for TB HIV-positive people provided with IPT 166 and relapse cases registered in Previously treated cases, excluding relapse, registered in HIV-positive TB cases, all types, registered in RR-/MDR-TB cases started on second-line treatment in XDR-TB cases started on second-line treatment in 211 Laboratories 213 Smear (per 1 population) 1.9 Culture (per 5 million population).5 Drug susceptibility testing (per 5 million population).1 Sites performing Xpert MTB/RIF 35 Financing TB control 214 National TB programme budget (US$ millions) 61 % Funded domestically 13% % Funded internationally 17% % Unfunded 69% (rate per 1 population per year) (rate per 1 population) (rate per 1 population per year) Population million Notified (new and relapse) (HIV+TB only) J 8 J and relapse excluding relapse HIV-positive Global Tuberculosis Report 214 Data for all years can be downloaded from
23 Viet Nam High TB burden High HIV burden High MDR-TB burden Estimates of TB burden a 213 Rate (per 1 population) 17 (12 24) 19 (13 26) Mortality (HIV+TB only) 2 ( ) 2.1 ( ) (includes HIV+TB) 19 (79 35) 29 (86 384) (includes HIV+TB) 13 (11 16) 144 ( ) (HIV+TB only) 9.4 (8 12) 1 (8.7 13) Case detection, all forms (%) 76 (63 91) Estimates of MDR-TB burden a 213 % of TB cases with MDR-TB 4 ( ) 23 (17 3) pulmonary TB cases 3 ( ) 2 1 ( ) TB case notifications 213 b Pulmonary, bacteriologically confirmed Pulmonary, clinically diagnosed Extrapulmonary Total new and relapse Previously treated, excluding relapses 1 81 Total cases notified Among 5 67 new cases: 143 (<1%) cases aged under 15 years; male:female ratio: 2.9 Reported cases of RR-/MDR-TB 213 Total b Cases tested for RR-/MDR-TB 353 (<1%) (45%) Laboratory-confirmed RR-/MDR-TB cases 1 24 Patients started on MDR-TB treatment 948 TB/HIV 213 TB patients with known HIV status (7) HIV-positive TB patients (6) HIV-positive TB patients on co-trimoxazole preventive therapy (CPT) 3 25 (72) HIV-positive TB patients on antiretroviral therapy (ART) (61) HIV-positive people screened for TB HIV-positive people provided with IPT and relapse cases registered in Previously treated cases, excluding relapse, registered in 212 HIV-positive TB cases, all types, registered in RR-/MDR-TB cases started on second-line treatment in XDR-TB cases started on second-line treatment in 211 Laboratories 213 Smear (per 1 population) 1.1 Culture (per 5 million population) 1.3 Drug susceptibility testing (per 5 million population).1 Sites performing Xpert MTB/RIF 27 Financing TB control 214 National TB programme budget (US$ millions) 73 % Funded domestically 9% % Funded internationally 18% % Unfunded 73% (rate per 1 population per year) (rate per 1 population) (rate per 1 population per year) Population million Notified (new and relapse) (HIV+TB only) and relapse excluding relapse HIV-positive Data for all years can be downloaded from Global Tuberculosis Report
Drug-resistant Tuberculosis
page 1/6 Scientific Facts on Drug-resistant Tuberculosis Source document: WHO (2008) Summary & Details: GreenFacts Context - Tuberculosis (TB) is an infectious disease that affects a growing number of
More informationTuberculosis in Myanmar Progress, Plans and Challenges
Tuberculosis in Myanmar Progress, Plans and Challenges Myanmar is one of the world s 22 high tuberculosis (TB) burden countries, with a TB prevalence rate three times higher than the global average and
More informationWorld Population to reach 10 billion by 2100 if Fertility in all Countries Converges to Replacement Level
UNITED NATIONS PRESS RELEASE EMBARGOED UNTIL 3 MAY 2011, 11:00 A.M., NEW YORK TIME World Population to reach 10 billion by if Fertility in all Countries Converges to Replacement Level UNITED NATIONS, 3
More informationManual on use of routine data quality assessment (RDQA) tool for TB monitoring. World Health Organization Stop TB Department, Geneva
Manual on use of routine data quality assessment (RDQA) tool for TB monitoring World Health Organization Stop TB Department, Geneva WHO Library Cataloguing in Publication Data Manual on use of routine
More informationThe Global Fund to Fight AIDS, Tuberculosis and Malaria Fourth Replenishment (2014-2016) Update on Results and Impact
The Global Fund to Fight AIDS, Tuberculosis and Malaria Fourth Replenishment (2014-2016) Update on Results and Impact April 2013 Executive Summary Over the last five years, the results of Global Fund-supported
More informationDr Malgosia Grzemska Global TB programme, WHO/HQ Meeting of manufacturers Copenhagen, Denmark, 23-26 November 2015
TB burden and treatment guidelines Dr Malgosia Grzemska Global TB programme, WHO/HQ Meeting of manufacturers Copenhagen, Denmark, 23-26 November 2015 Outline Latest epidemiological data Global programme
More informationUse of high burden country lists for TB by WHO in the post-2015 era
Use of high burden country lists for TB by WHO in the post-2015 era Discussion paper initially prepared in April 2015 to facilitate feedback, and finalized after the June 2015 meeting of WHO s Strategic
More informationKenya Joint TB/HIV Concept Note Development
Kenya Joint TB/HIV Concept Note Development Market Place Presentation Outline Introduction TB HIV NFM goals, objectives and indicators TB HIV CN allocation Kenya joint TB HIV programming TB HIV actors
More informationPRESS RELEASE WORLD POPULATION TO EXCEED 9 BILLION BY 2050:
PRESS RELEASE Embargoed until 12:00 PM, 11 March, 2009 WORLD POPULATION TO EXCEED 9 BILLION BY 2050: Developing Countries to Add 2.3 Billion Inhabitants with 1.1 Billion Aged Over 60 and 1.2 Billion of
More informationEligibility List 2015
The Global Fund adopted an allocation-based approach for funding programs against HIV/AIDS, TB and malaria in 2013. The Global Fund policy states that countries can receive allocation only if their components
More informationThe Role of the Health Service Administrator in TB Control. National Tuberculosis Control Programme
The Role of the Health Service Administrator in TB Control Goal/Objectives of NTP Mandate: To provide leadership for the health sector response to combat Tuberculosis in Ghana. Goal: To reduce the burden
More informationEVERY YEAR 9 MILLION PEOPLE GET SICK WITH TB. 3 MILLION DON T GET THE CARE THEY NEED. HELP US REACH THEM. LEAVE NO ONE BEHIND.
EVERY YEAR 9 MILLION PEOPLE GET SICK WITH TB. 3 MILLION DON T GET THE CARE THEY NEED. HELP US REACH THEM. LEAVE NO ONE BEHIND. Help achieve zero deaths and put an end to the global TB epidemic. What does
More informationDefinitions and reporting framework for tuberculosis 2013 revision (updated December 2014)
Definitions and reporting framework for tuberculosis 2013 revision (updated December 2014) Cover photos: WHO Photo Library Top, Nepal (C. Black); middle, Afghanistan (C. Black); bottom, China (S. Lim)
More informationOut of Step Deadly implementation gaps. A survey of TB diagnostic and treatment practices in eight countries. October 2014. www.msfaccess.
Out of Step Deadly implementation gaps in the TB response A survey of TB diagnostic and treatment practices in eight countries October 2014 www.msfaccess.org About Médecins Sans Frontières (MSF) MSF is
More informationMODULE THREE TB Treatment. Treatment Action Group TB/HIV Advocacy Toolkit
MODULE THREE TB Treatment Treatment Action Group TB/HIV Advocacy Toolkit 1 Topics to be covered TB treatment fundamentals Treatment of TB infection and disease TB treatment research Advocacy issues 2 Section
More informationCollaborative TB and HIV Services for Drug Users. Christian Gunneberg M.O. WHO
Collaborative TB and HIV Services for Drug Users Christian Gunneberg M.O. WHO What I will address The problems of HIV/TB and Drug use. The policy guide. What next. Drug use and HIV Drug users are a large
More informationProtocol for the Control of Tuberculosis
Protocol QH-HSDPTL-040-1:2015 Effective Date: 11 November 2015 Review Date: 11 November 2018 Supersedes: Protocol QH-HSDPTL-040-1:2013 QH-HSDPTL-040-2:2013 QH-HSDPTL-040-3:2013 Health Service Directive
More informationGlobal Update on HIV Treatment 2013: Results, Impact and Opportunities
June 2013 Global Update on HIV Treatment 2013: Results, Impact and Opportunities WHO/UNAIDS/UNICEF v2 Outline Results: Progress towards Global Targets - Antiretroviral treatment - Prevention of mother-to-child
More informationReferral Guidelines for TB/HIV co-management. (First Edition)
Referral Guidelines for TB/HIV co-management (First Edition) Government of Lesotho April 2011 1 REFERRAL GUIDELINES FOR TB/HIV CO-MANAGEMENT INTRODUCTION Many TB patients are infected with HIV. Many people
More informationTB Prevention, Diagnosis and Treatment. Accelerating advocacy on TB/HIV 15th July, Vienna
TB Prevention, Diagnosis and Treatment Accelerating advocacy on TB/HIV 15th July, Vienna Diagnosis Microscopy of specially stained sputum is the main test for diagnosing TB (1 2 days) TB bacilli seen in
More informationGeneral Information on Tuberculosis
General Information on Tuberculosis ON THE MOVE AGAINST TUBERCULOSIS: Transforming the fi ght towards elimination World TB Day 2011 SAARC Tuberculosis & HIV/AIDS Centre GPO Box No 9517, Kathmandu, Nepal
More informationAFRICAN UNION ROADMAP: PROGRESS IN THE FIRST YEAR
AFRICAN UNION ROADMAP: PROGRESS IN THE FIRST YEAR Update on progress to implement the African Union Roadmap on Shared Responsibility and Global Solidarity for AIDS, TB and Malaria Response in Africa (2012
More informationTuberculosis OUR MISSION THE OPPORTUNITY
Tuberculosis OUR MISSION Guided by the belief that every life has equal value, the Bill & Melinda Gates Foundation works to help all people lead healthy, productive lives. Our Global Health Program is
More information2ND FORUM OF NATIONAL STOP TB PARTNERSHIP IN SOUTH EAST ASIA, WEST PACIFIC AND EAST MEDITERRANEAN REGIONS 3 4 MARCH 2014 - JAKARTA, INDONESIA
2ND FORUM OF NATIONAL STOP TB PARTNERSHIP IN SOUTH EAST ASIA, WEST PACIFIC AND EAST MEDITERRANEAN REGIONS 3 4 MARCH 2014 - JAKARTA, INDONESIA The Stop TB Partnership Indonesia is a partnership group comprising
More informatione-tb Manager: A Comprehensive Web-Based Tool for Programmatic Management
e-tb Manager: A Comprehensive Web-Based Tool for Programmatic Management of TB and Drug-Resistant TB Management Sciences for Health Facts about TB* TB is contagious and airborne; each untreated person
More informationUPDATE UNAIDS 2016 DATE 2016
GLOBAL AIDS UP GLOBAL AIDS UPDATE UNAIDS 2016 DATE 2016 ENORMOUS GAINS, PERSISTENT CHALLENGES The world has committed to ending the AIDS epidemic by 2030. How to reach this bold target within the Sustainable
More informationGuideline. Treatment of tuberculosis in patients with HIV co-infection. Version 3.0
Guideline Treatment of tuberculosis in patients with HIV co-infection Version 3.0 Key critical points Co-infection with Tuberculosis (TB) and HIV is common in many parts of the world, especially sub-saharan
More informationThe Platform. for. Human Resource Development for TB. Five years exchange of global experience
The Platform for Human Resource Development for TB Five years exchange of global experience 1 The Global Health Bureau, Office of Health, Infectious Disease and Nutrition (HIDN), US Agency for International
More informationTuberculosis and HIV/AIDS Co-Infection: Epidemiology and Public Health Challenges
Tuberculosis and HIV/AIDS Co-Infection: Epidemiology and Public Health Challenges John B. Kaneene, DVM, MPH, PhD University Distinguished Professor of Epidemiology Director, Center for Comparative Epidemiology
More informationCHANGES TO BERMUDA WORK PERMIT POLICIES EFFECTIVE DECEMBER 2014
CHANGES TO BERMUDA WORK PERMIT POLICIES EFFECTIVE DECEMBER 2014 Bermuda s Ministry of Home Affairs issued for consultation in October 2014 proposed changes to the Work Permit Policy to be made effective
More informationRichard H. Needle, PhD, MPH Lin Zhao, PhD candidate (UCSF School of Nursing) CSIS Africa Program Roundtable June 10, 2010
Richard H. Needle, PhD, MPH Lin Zhao, PhD candidate (UCSF School of Nursing) CSIS Africa Program Roundtable June 10, 2010 Reference Group to the United Nations on HIV and Injecting Drug Use 2010 Mathers:
More informationGuidance on how to measure contributions of public-private mix to TB control
Guidance on how to measure contributions of public-private mix to TB control Project report to the Tuberculosis Control Assistance Programme (TB CAP) Project number: APA4, C3-01 The World Health Organization
More informationA Comprehensive Global Public Health
A Comprehensive Global Public Health Strategy & Engaging the Supply Chain Dr. Rick Wilkins March, 2009 2009 Chevron Corporation Global Public Health HIV/AIDS, Tuberculosis, and Malaria Attention to these
More informationTreatment of tuberculosis. guidelines. Fourth edition
Treatment of tuberculosis guidelines Fourth edition Treatment of tuberculosis Guidelines Fourth edition WHO Library Cataloguing-in-Publication Data: Treatment of tuberculosis: guidelines 4th ed. WHO/HTM/TB/2009.420
More informationManagement of Tuberculosis: Indian Guidelines
Chapter 105 Management of Tuberculosis: Indian Guidelines Kuldeep Singh Sachdeva INTRODUCTION Tuberculosis (TB) is an infectious disease caused predominantly by Mycobacterium tuberculosis and among the
More informationSummary and Key Points
Summary and Key Points The World Malaria Report 2011 summarizes information received from 106 malaria-endemic countries and other sources and updates the analyses presented in the 2010 report. It highlights
More informationTime to act Save a million lives by 2015 Prevent and treat tuberculosis among people living with HIV
Time to act Save a million lives by 2015 Prevent and treat tuberculosis among people living with HIV Living with HIV, dying from tuberculosis A THIEF IN OUR MIDST We live in a time of unprecedented hope
More informationTB Case Definitions Revision May 2011
TB Case Definitions Revision May 2011 Table of contents TABLE OF CONTENTS 1 1. BACKGROUND 3 2. CURRENT WHO DEFINITIONS OF CASES AND TREATMENT OUTCOMES 4 3. COMMENTARY ON CURRENT WHO DEFINITIONS OF CASES
More informationCountries Ranked by Per Capita Income A. IBRD Only 1 Category iv (over $7,185)
Page 1 of 5 Note: This OP 3.10, Annex C replaces the version dated September 2013. The revised terms are effective for all loans that are approved on or after July 1, 2014. Countries Ranked by Per Capita
More informationChapter 3 South African guidelines and introduction to clinical cases
Chapter 3 South African guidelines and introduction to clinical cases 3.1. South African national antiretroviral guidelines When this book was published in 2012 the current national antiretroviral treatment
More informationSession 4: The Drug Management Cycle: Selection. David Peters
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike License. Your use of this material constitutes acceptance of that license and the conditions of use of materials on this
More informationEntrance Health Certificate
Entrance Health Certificate 1 Wheelock College Student Health Service ENTRANCE HEALTH CERTIFICATE The Entrance Health Certificate must be completed in its entirety and brought with you to Boston. Admission
More informationRevised National Tuberculosis Control Programme (RNTCP) Dr. NAVPREET
Revised National Tuberculosis Control Programme (RNTCP) Dr. NAVPREET Assistant Prof., Deptt. of Community Medicine GMCH Chandigarh Problem Statement of TB in India India accounts for nearly 1/4 th of global
More informationUnited Kingdom Human Trafficking Centre National Referral Mechanism Statistics 2013
United Kingdom Human Trafficking Centre National Referral Mechanism Statistics 2013 Date 20/01/2014 Version number V1.0 NRM Statistics 2013 1 NOT PROTECTIVELY MARKED In 2013 the UK National Referral Mechanism
More informationProforma Cost for international UN Volunteers for UN Partner Agencies for 2016. International UN Volunteers (12 months)
Proforma Cost for international UN Volunteers for UN Partner Agencies for 2016 Country Of Assignment International UN Volunteers (12 months) International UN Youth Volunteers (12 months) University Volunteers
More informationExpression of Interest in Research Grant Applications
INTERNATIONAL CENTRE FOR GENETIC ENGINEERING AND BIOTECHNOLOGY THE ACADEMY OF SCIENCES FOR THE DEVELOPING WORLD UNITED NATIONS EDUCATIONAL, SCIENTIFIC AND CULTURAL ORGANIZATION ICGEB-TWAS-UNESCO/IBSP Joint
More informationYear 1. Annual Report. October 1, 2014 September 30, 2015
Challenge TB - Malawi Year Annual Report October, 204 September 30, 205 October 30, 205 This report was made possible through the support for Challenge TB provided by the United States Agency for International
More informationWorld Health Organization Department of Communicable Disease Surveillance and Response
WHO/CDS/CSR/ISR/2000.1 WHO Report on Global Surveillance of Epidemic-prone Infectious Diseases World Health Organization Department of Communicable Disease Surveillance and Response This document has been
More informationTREATING DRUG-SENSITIVE TB IN INDIA: IMPLEMENTATION OF DAILY THERAPY WITH FIXED DOSE COMBINATIONS
TREATING DRUG-SENSITIVE TB IN INDIA: IMPLEMENTATION OF DAILY THERAPY WITH FIXED DOSE COMBINATIONS Policy brief, March 2015 Tuberculosis (TB), a communicable disease that affects 9 million people worldwide,
More informationU.S. President s Malaria Initiative (PMI) Approach to Health Systems Strengthening
U.S. President s Malaria Initiative (PMI) Approach to Health Systems Strengthening What is Health System Strengthening? Strengthening health systems means supporting equitable and efficient delivery of
More informationDiagnostic Network & Treatment Strengthening Strategies in USAID-Priority Countries
Diagnostic Network & Treatment Strengthening Strategies in USAID-Priority Countries Amy Piatek (on behalf of) USAID/Global Health Bureau Washington DC April 29, 2015 The United States Government Lantos-Hyde
More informationCOVER: 4-year-old Jan Carlos jumps on his parents bed. The family reported a significant drop in the number of malaria cases since
Results Report 215 COVER: 4-year-old Jan Carlos jumps on his parents bed. The family reported a significant drop in the number of malaria cases since insecticide-treated nets were distributed two years
More informationUNAIDS World AIDS Day Report 2012
UNAIDS World AIDS Day Report 212 Results 1 Foreword The sun finds a way to shine into even the deepest parts of the forest. It is a metaphor for all of us who are working to restore hope and dignity around
More informationBrain Drain and Brain Gain: Selected Country Experiences and Responses
Brain Drain and Brain Gain: Selected Country Experiences and Responses Manuel M. Dayrit MD, MSc Dean, Ateneo School of Medicine and Public Health Manila, Philippines manuel_m_dayrit@yahoo.com Australia,
More informationTable 5: HIV/AIDS statistics for Africa (excluding North Africa), 2001 and 2009
Table 5: HIV/AIDS statistics for Africa (excluding North Africa), 2001 and 2009 Year People living with HIV (million) People newly infected with HIV (million) Children living with HIV (million) AIDS-related
More informationA HISTORY OF THE HIV/AIDS EPIDEMIC WITH EMPHASIS ON AFRICA *
UN/POP/MORT/2003/2 5 September 2003 ENGLISH ONLY WORKSHOP ON HIV/AIDS AND ADULT MORTALITY IN DEVELOPING COUNTRIES Population Division Department of Economic and Social Affairs United Nations Secretariat
More informationPrinciples and Structure of a Research Protocol. The Union, Paris, France MSF, Brussels, Belgium
Principles and Structure of a Research Protocol The Union, Paris, France MSF, Brussels, Belgium BASIC STRUCTURE Background and rationale to study Aim and objectives (the research question) Methods (includes
More informationGUIDELINES FOR TUBERCULOSIS PREVENTIVE THERAPY AMONG HIV INFECTED INDIVIDUALS IN SOUTH AFRICA
GUIDELINES FOR TUBERCULOSIS PREVENTIVE THERAPY AMONG HIV INFECTED INDIVIDUALS IN SOUTH AFRICA 2010 1 TB prophylaxis GUIDELINES FOR TUBERCULOSIS PREVENTIVE THERAPY AMONG HIV INFECTED INDIVIDUALS Background
More informationDRUG-RESISTANT TB SURVEILLANCE & RESPONSE SUPPLEMENT GLOBAL TUBERCULOSIS REPORT 2014
DRUG-RESISTANT TB SURVEILLANCE & RESPONSE SUPPLEMENT GLOBAL TUBERCULOSIS REPORT 2014 World Health Organization 2014 All rights reserved. Publications of the World Health Organization are available on the
More informationFDI performance and potential rankings. Astrit Sulstarova Division on Investment and Enterprise UNCTAD
FDI performance and potential rankings Astrit Sulstarova Division on Investment and Enterprise UNCTAD FDI perfomance index The Inward FDI Performance Index ranks countries by the FDI they receive relative
More informationNET INTERNATIONAL MIGRATION
II. NET INTERNATIONAL MIGRATION A. GLOBAL TRENDS During the period 195-21, the developed regions experienced population gains from positive net international migration while the developing regions were
More informationTuberculosis Prevention and Control Protocol, 2008
Tuberculosis Prevention and Control Protocol, 2008 Preamble The Ontario Public Health Standards (OPHS) are published by the Minister of Health and Long- Term Care under the authority of the Health Protection
More informationSummary of GAVI Alliance Investments in Immunization Coverage Data Quality
Summary of GAVI Alliance Investments in Immunization Coverage Data Quality The GAVI Alliance strategy and business plan for 2013-2014 includes a range of activities related to the assessment and improvement
More informationDISCLAIMER. www.health.gov.fj
DISCLAIMER The authors do not warrant the accuracy of the information contained in the TB Technical Guideline and do not take responsibility for any death, loss, damage or injury caused by using the information
More informationFacilitating Economic Integration in Asia-Pacific through Aid for Trade. 23 April 2014 // Tunis Mia Mikic Teemu Alexander Puutio
Facilitating Economic Integration in Asia-Pacific through Aid for Trade 23 April 2014 // Tunis Mia Mikic Teemu Alexander Puutio ODA finally on the rebound Globally development aid rose by 6.1% in real
More informationNorwegian Climate Finance 2010.
Norwegian Climate Finance 2010. In Decision 1/CP.16 (Cancun Agreements AWGLCA outcome), relevant parties were invited to submit information on the resources provided for the fast start period (2010 2012).
More informationHaemophilus influenzaetype b (Hib) Vaccination Position Paper. July 2013
Haemophilus influenzaetype b (Hib) Vaccination Position Paper July 2013 Hib burden-pre vaccine era In 2000, before widespread introduction of Hib vaccine in resource-poor countries, Hib caused: 8.13 million
More informationTB preventive therapy in children. Introduction
TB preventive therapy in children H S Schaaf Department of Paediatrics and Child Health, and Desmond Tutu TB Centre Stellenbosch University, and Tygerberg Children s Hospital Introduction Children are
More informationSUMMARY OF VOLUNTARY PRINCIPLES IMPLEMENTATION EFFORTS DURING 2012
SUMMARY OF VOLUNTARY PRINCIPLES IMPLEMENTATION EFFORTS DURING 2012 This report provides an overview of Participants efforts to implement the Voluntary Principles on Security and Human Rights (the Voluntary
More informationTotal Purchases in 2012
Fighting Hunger Worldwide Food Procurement Annual Report 2012 Maize, Niger WFP/Rein Skullerud Procurement Mission Statement To ensure that appropriate commodities are available to WFP beneficiaries in
More informationGlobal Update on HIV Treatment 2013: Results, Impact and Opportunities. HIV treatment
EMBARGO: till 12:00 noon, Kuala Lumpur time; 04:00 am GMT, 30 June 2013 HIV treatment Global Update on HIV Treatment 2013: Results, Impact and Opportunities June 2013 WHO Library Cataloguing-in-Publication
More informationQ&A on methodology on HIV estimates
Q&A on methodology on HIV estimates 09 Understanding the latest estimates of the 2008 Report on the global AIDS epidemic Part one: The data 1. What data do UNAIDS and WHO base their HIV prevalence estimates
More informationINFORMATION BULLETIN RECOGNITION OF QUALIFICATIONS & EQUIVALENCE OF DEGREES
INFORMATION BULLETIN 2009 RECOGNITION OF QUALIFICATIONS & EQUIVALENCE OF DEGREES ASSOCIATION OF INDIAN UNIVERSITIES 16 COMRADE INDRAJIT GUPTA MARG NEW DELHI 110 002 0 AN INTRODUCTION : The Inter University
More informationTHE GAP REPORT UNAIDS
THE GAP REPORT UNAIDS 1 Our mission is to build a better world. To leave no one behind. To stand for the poorest and the most vulnerable in the name of global peace and social justice. Ban Ki-moon United
More informationNo. prev. doc.: 9392/08 SAN 77 DENLEG 48 VETER 5 Subject: EMPLOYMENT, SOCIAL POLICY, HEALTH AND CONSUMER AFFAIRS COUNCIL MEETING ON 9 AND 10 JUNE 2008
COUNCIL OF THE EUROPEAN UNION Brussels, 22 May 2008 9637/08 SAN 88 DENLEG 52 VETER 7 NOTE from: Committee of Permanent Representatives (Part 1) to: Council No. prev. doc.: 9392/08 SAN 77 DENLEG 48 VETER
More informationTHE GAP REPORT UNAIDS
THE GAP REPORT UNAIDS 1 Our mission is to build a better world. To leave no one behind. To stand for the poorest and the most vulnerable in the name of global peace and social justice. Ban Ki-moon United
More informationMonthly Report on Asylum Applications in The Netherlands and Europe
Asylum Trends Monthly Report on Asylum Applications in The Netherlands and Europe November 2013 2014 November 2014 Colophon Title Subtitle Author Asylum Trends Monthly Report on Asylum Applications in
More informationThe Effective Vaccine Management Initiative Past, Present and Future
EVM setting a standard for the vaccine supply chain The Effective Vaccine Management Initiative Past, Present and Future Paul Colrain TechNet meeting Dakar, Senegal, February 2013 February 2013 TechNet
More informationEARLY MARRIAGE A HARMFUL TRADITIONAL PRACTICE A STATISTICAL EXPLORATION
EARLY MARRIAGE A HARMFUL TRADITIONAL PRACTICE A STATISTICAL EXPLORATION EARLY MARRIAGE A HARMFUL TRADITIONAL PRACTICE A STATISTICAL EXPLORATION CONTENTS I. INTRODUCTION......................................................1
More informationMEETING THE INVESTMENT CHALLENGE TIPPING THE DEPENDENCY BALANCE
BREAKING NEWS MEETING THE INVESTMENT CHALLENGE TIPPING THE DEPENDENCY BALANCE Domestic investments exceed international investments total reaching US$ 8.6 billion. 40 countries fund more than 70% of their
More informationOPEN LETTER Re: Cartridge prices, extended warranties and business in Russia and the People s Republic of China
6 January 2014 Mr. John L. Bishop Chief Executive Officer Cepheid 904 Caribbean Drive Sunnyvale, CA 94089 USA OPEN LETTER Re: Cartridge prices, extended warranties and business in Russia and the People
More informationAcknowledgments. For further information, please contact D Arcy Richardson, PATH TB Technical Director, at drichardson@path.org.
Acknowledgments This MDR/XDR-TB Assessment and Monitoring Tool was produced for review by the United States Agency for International Development. It was prepared by PATH for the Tuberculosis Support Contract
More informationBelgian Technical Cooperation (BTC) for printing of this manual
A practical guide for TB and HIV service Integration at Integration at Primary health care Primary health care facilities A practical guide for TB and HIV service facilities 1 Acknowledgements Belgian
More informationTuberculosis STRATEGY OVERVIEW OUR MISSION THE OPPORTUNITY OUR STRATEGY
Tuberculosis STRATEGY OVERVIEW OUR MISSION Guided by the belief that all lives have equal value, the Bill & Melinda Gates Foundation works to help all people lead healthy, productive lives. Our Global
More informationEvidence-based best practices to reduce maternal mortality
Evidence-based best practices to reduce maternal mortality Presented at the HerDignity Network Webinar 8 October 2014 Monique V. Chireau, MD, MPH Assistant Professor, Department of OB/GYN Duke University
More informationPolicy Paper 12. Education for All Global Monitoring Report. Increasing tax revenues to bridge the education financing gap
Education for All Global Monitoring Report Policy Paper 12 March 2014 Increasing tax revenues to bridge the education financing gap Sustained economic growth has increased the resources that many of the
More informationGoal 2: Achieve Universal Primary Education
92 Goal 2: Achieve Universal Primary Education In eight economies in the region including a number from the Pacific, total net enrollment ratios in primary education are below 80%. Eleven economies including
More informationDSV Air & Sea, Inc. Aerospace Sector. DSV Air & Sea, Inc. Aerospace
DSV Air & Sea, Inc. Aerospace Sector DSV Air & Sea, Inc. Aerospace Introduction to DSV DSV is a global supplier of transport and logistics services. We have offices in more than 70 countries and an international
More informationAnnexure 1. 1. India s FTA/PTA and RMG Trade with FTA/PTA Partners
Annexure 1 1. India s FTA/PTA and RMG Trade with FTA/PTA Partners The size of India s clothing industry is estimated to be US$ 62 bn. in 2012 as per FICCI and Textile committee estimates including exports
More informationHow To Calculate The Incidence Of Mycobacterium Tuberculosis
Burden of childhood tuberculosis in 22 high-burden countries: a mathematical modelling study Peter J Dodd, Elizabeth Gardiner, Renia Coghlan, James A Seddon Summary Background Confirmation of a diagnosis
More informationGeneration 2025 and beyond. Occasional Papers No. 1, November 2012. Division of Policy and Strategy
Occasional Papers No. 1, November 212 Division of Policy and Strategy Danzhen You and David Anthony Generation 225 and beyond The critical importance of understanding demographic trends for children of
More informationI. World trade developments
I. World trade developments World merchandise exports grew by 2 per cent in value terms in 2013 while exports of commercial services increased by per cent. Key developments in 2013: a snapshot Trade data
More informationElectronic Patient Management System epms Zimbabwe
Electronic Patient Management System epms Zimbabwe Collecting and Managing Data at the Patient Level for Better Treatment and Care Having access to patient health information enables medical professionals
More informationIMA Knowledge June, 2015
Tuberculosis is a major public health problem in India. Early diagnosis and complete treatment of TB is the corner-stone of TB prevention and control strategy. India's Revised National TB Control program(rntcp)
More informationBENJAMIN V. LOZARE Director for Training and Capacity Building
BENJAMIN V. LOZARE Director for Training and Capacity Building Dr. Lozare leads the JHU CCP Training and Capacity Building activities and the development of SCOPE (Strategic Communication Planning and
More informationContent Introduction. Pag 3. Introduction. Pag 4. The Global Fund in Zimbabwe. Pag 5. The Global Fund Grant Portfolio in Zimbabwe.
Content Introduction The Global Fund in Zimbabwe The Global Fund Grant Portfolio in Zimbabwe Capacity Development 2009-2014 Capacity Development and Transition Planning 2014 Overview of the Capacity Development
More informationA Practical Handbook for National TB Laboratory Strategic Plan Development
A Practical Handbook for National TB Laboratory Strategic Plan Development PARTICIPANTS MANUAL TB CARE A Practical Handbook for National TB Laboratory Strategic Plan Development Participants Manual Second
More informationFundamentals of Energy Infrastructure Security: Risk Mitigation in the International Environment
Brochure More information from http://www.researchandmarkets.com/reports/306049/ Fundamentals of Energy Infrastructure Security: Risk Mitigation in the International Environment Description: The world's
More informationChildhood Tuberculosis Some Basic Issues. Jeffrey R. Starke, M.D. Baylor College of Medicine
Childhood Tuberculosis Some Basic Issues Jeffrey R. Starke, M.D. Baylor College of Medicine TUBERCULOSIS IS A SOCIAL DISEASE WITH MEDICAL IMPLICATIONS THE GREAT PARADOX OF TUBERCULOSIS A CAUTIONARY TALE
More informationInvestment in developing countries' food and agriculture: Assessing agricultural capital stocks and their impact on productivity
Investment in developing countries' food and agriculture: Assessing agricultural capital stocks and their impact on productivity Gustavo Anriquez (FAO), Hartwig de Haen, Oleg Nivyevskiy & Stephan von Cramon
More information